Sage Therapeutics
Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.
Sage Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for brexanolone (SAGE-547) to treat postpartum depression (PPD).
Martin Shkreli’s actions were brash and often bizarre, but served as a catalyst for the pharma pricing debate.
A look at three small biotechs that big drugmakers are drooling over.
During the J.P. Morgan Healthcare Conference, Sage provided an update on its long-term strategy to drive growth at the company.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
Shares of Sage have shot up more than 75 percent this morning as a result of the impressive data.
JOBS
IN THE PRESS